Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Metabolomics. 2020 Jun 18;16(7):75. doi: 10.1007/s11306-020-01696-w.
Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors.
We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile.
In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data.
Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11).
KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile.
Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.
低钾摄入可能会影响心血管疾病（CVD）风险和心脏代谢风险因素。
我们假设氯化钾（KCl）补充剂可以改善心血管风险代谢组学特征。
在这项针对 26 名患有前驱糖尿病的参与者的随机临床试验（RCT）的二次分析中，我们对基线和 12 周（研究结束时）的血浆样本进行了基于靶向质谱的代谢组学分析。主成分分析（PCA）用于将许多相关代谢物简化为较少的独立因素，这些因素保留了原始数据中的大部分信息。
服用 KCl 的参与者的支链氨基酸（BCAA）因子（P=0.004）和缬氨酸水平（P=0.02）显著降低（对应于较低的心血管风险）；而短链酰基辅酶 A（SCA）因子的降低则不显著（P=0.11）。
KCl 补充剂可能会改善循环中的 BCAA 水平，这可能反映出整体心脏代谢风险状况的改善。
Clinicaltrials.gov 标识符：NCT02236598；https://clinicaltrials.gov/ct2/show/NCT02236598。
